The Janssen Pharmaceutical Companies of Johnson & Johnson today announced initial results from the Phase 3 MAGNITUDE study evaluating the investigational use of niraparib, a selective poly-ADP ribose polymerase (PARP) inhibitor, in combination with abiraterone acetate plus prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) with or without specific homologous recombination repair (HRR) gene…
eTurboNews labarai na masu biyan kuɗi ne kawai. Biyan kuɗi shine FREE.
Masu biyan kuɗi suna shiga nan Danna nan don biyan kuɗi FREE
Masu biyan kuɗi suna shiga nan Danna nan don biyan kuɗi FREE
ABUBUWAN DA ZA KU GUDU DAGA WANNAN LABARI:
- Johnson today announced initial results from the Phase 3 MAGNITUDE study evaluating the investigational use of niraparib, a selective poly-ADP ribose polymerase (PARP) inhibitor, in combination with abiraterone acetate plus prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) with or without specific homologous recombination repair (HRR) gene….
- Biyan kuɗi kyauta ne.
- eTurboNews labarai na masu biyan kuɗi ne kawai.
